

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Novartis Bioventures Ltd</u>  (Last) (First) (Middle) <u>C/O NOVARTIS INTERNATIONAL AG</u> <u>LICHTSTRASSE 35</u>  (Street) <u>BASEL V8 CH-4056</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Altimmune, Inc. [ ALT ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>02/13/2018</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)  <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, par value \$0.0001	02/13/2018		J <sup>(1)</sup>		269,527	A	(1)	2,804,088	I	See Footnote <sup>(2)</sup>
Common Stock, par value \$0.0001	02/15/2018		J <sup>(3)</sup>		67,925	A	(3)	2,872,013	I	See Footnote <sup>(2)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series B Convertible Preferred Stock	\$2.67 <sup>(4)</sup>	02/13/2018		J <sup>(1)</sup>		344.9398		08/21/2017	08/15/2018	Common Stock, par value \$0.0001	129,188	(1)	1,724.6878	I	See Footnote <sup>(2)</sup>

1. Name and Address of Reporting Person\*  
Novartis Bioventures Ltd  
  
 (Last) (First) (Middle)  
C/O NOVARTIS INTERNATIONAL AG  
LICHTSTRASSE 35  
  
 (Street)  
BASEL V8 CH-4056  
  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
NOVARTIS AG  
  
 (Last) (First) (Middle)  
C/O NOVARTIS INTERNATIONAL AG  
LICHTSTRASSE 35  
  
 (Street)  
BASEL V8 CH-4056  
  
 (City) (State) (Zip)

**Explanation of Responses:**

- Pursuant to the terms of the Series B Convertible Preferred Stock (the "Preferred Stock"), the Issuer converted the Preferred Stock into shares of the Issuer's common stock, par value \$0.0001 per share (the "Common Stock") at the installment conversion price of \$1.2798 per share of Common Stock.
- The board of directors of Novartis Bioventures Ltd has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd is an indirectly owned subsidiary of Novartis AG.

3. Pursuant to the terms of the Series B Convertible Preferred Stock (the "Preferred Stock"), the Issuer converted the Preferred Stock into shares of the Issuer's common stock, par value \$0.0001 per share (the "Common Stock") at the installment conversion price of \$1.2408 per share of Common Stock.

4. The Issuer's Preferred Stock is convertible at any time at the option of the holder into shares of the Issuer's Common Stock, subject to certain restrictions, at an initial conversion price of \$2.67 per share and a stated amount of \$1,000 per share.

**Remarks:**

/s/ Bart Dzikowski, Secretary of  
the Board of Novartis                      02/15/2018  
Bioventures Ltd

/s/ Stephan Sandmeier,  
Authorized Signatory of                      02/15/2018  
Novartis Bioventures Ltd

/s/ Bart Dzikowski, Authorized  
Signatory of Novartis AG                      02/15/2018

/s/ Stephan Sandmeier,  
Authorized Signatory of                      02/15/2018  
Novartis AG

\*\* Signature of Reporting Person                      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**